Kevin R. Parker

机构：Enable Biosciences (United States), Stanford University · ORCID：0000-0001-5532-238X

发表论文 66 篇 · 总被引 5456 次 · h-index 22

代表论文

• Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells (2023 · Cell · 被引 198)
• Bidirectional epigenetic editing reveals hierarchies in gene regulation (2024 · Nature Biotechnology · 被引 45)
• CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity (2023 · Journal for ImmunoTherapy of Cancer · 被引 35)
• Data from NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity (2023)
• Data from NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity (2023)
• Supplementary Data from NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity (2023)